Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience.
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Colorectal Neoplasms
/ drug therapy
Drug Administration Schedule
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Neoplasm Metastasis
Phenylurea Compounds
/ administration & dosage
Progression-Free Survival
Pyridines
/ administration & dosage
Pyrrolidines
/ administration & dosage
Thymine
/ administration & dosage
Trifluridine
/ administration & dosage
Regorafenib
real-world practice
refractory metastatic colorectal cancer
trifluridine/tipiracil
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
20
03
2021
revised:
27
03
2021
accepted:
29
03
2021
entrez:
6
5
2021
pubmed:
7
5
2021
medline:
14
5
2021
Statut:
ppublish
Résumé
Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have have been shown to improve overall survival in patients with refractory metastatic colorectal cancer. The aim of our study was to evaluate the efficacy and safety profiles of these agents administered in sequence in real world practice. Clinical data of patients treated beyond the 2°line with REG or FTD/TPI between January 2016 and August 2020, were retrospectively collected from eight institutes in the Lazio Region. We included 49 patients treated with both drug sequences. A total of 28 G3/G4 toxicity events (53.8%) were recorded in the FTD/TPI-to-REG sequence vs. 24 (46.1%) in the reverse sequence. Median overall survival for the patients included in the FTP/TPI-to-REG group was 20 months (95%CI=16.7-23.3) vs. 27 months in the reverse group (95%CI=17.8-36.2). The disease control rate was 45.0% for patients treated with the REG-to-FTD/TPI sequence vs. 24.1% in those treated with the FTD/TPI-to-REG sequence (p=0.18). The sequence REG-to-FTD/TPI and vice versa can extend survival, whereas only REG-to-FTD/TPI stabilizes cancer growth.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have have been shown to improve overall survival in patients with refractory metastatic colorectal cancer. The aim of our study was to evaluate the efficacy and safety profiles of these agents administered in sequence in real world practice.
PATIENTS AND METHODS
METHODS
Clinical data of patients treated beyond the 2°line with REG or FTD/TPI between January 2016 and August 2020, were retrospectively collected from eight institutes in the Lazio Region.
RESULTS
RESULTS
We included 49 patients treated with both drug sequences. A total of 28 G3/G4 toxicity events (53.8%) were recorded in the FTD/TPI-to-REG sequence vs. 24 (46.1%) in the reverse sequence. Median overall survival for the patients included in the FTP/TPI-to-REG group was 20 months (95%CI=16.7-23.3) vs. 27 months in the reverse group (95%CI=17.8-36.2). The disease control rate was 45.0% for patients treated with the REG-to-FTD/TPI sequence vs. 24.1% in those treated with the FTD/TPI-to-REG sequence (p=0.18).
CONCLUSION
CONCLUSIONS
The sequence REG-to-FTD/TPI and vice versa can extend survival, whereas only REG-to-FTD/TPI stabilizes cancer growth.
Identifiants
pubmed: 33952483
pii: 41/5/2553
doi: 10.21873/anticanres.15033
doi:
Substances chimiques
Phenylurea Compounds
0
Pyridines
0
Pyrrolidines
0
regorafenib
24T2A1DOYB
tipiracil
NGO10K751P
Thymine
QR26YLT7LT
Trifluridine
RMW9V5RW38
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2553-2561Informations de copyright
Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.